McLean Hospital - Harvard Medical School, 115 Mill Street, Belmont, MA, 02478, USA.
National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA.
Psychopharmacology (Berl). 2017 Dec;234(23-24):3455-3465. doi: 10.1007/s00213-017-4731-5. Epub 2017 Sep 9.
The therapeutic potential of monoamine releasers with prominent dopaminergic effects is hindered by their high abuse liability.
The present study examined the effects of several novel "norepinephrine (NE)-preferring" monoamine releasers relative to non-selective monoamine releasers, d-amphetamine and d-methamphetamine, in rhesus monkeys trained to discriminate cocaine. NE-preferring releasers were approximately 13-fold more potent for NE compared to dopamine release and ranged in potency for serotonin release (PAL-329 < l-methamphetamine < PAL-169).
Adult rhesus macaques were trained to discriminate 0.4 mg/kg, IM cocaine on a 30-response fixed ratio schedule of food reinforcement. Substitution studies determined the extent to which test drugs produced cocaine-like discriminative stimulus effects and their time course. Drug interaction studies determined whether pretreatment with test drugs altered the discriminable effects of cocaine.
Results show that cocaine, d-amphetamine, and d-methamphetamine dose-dependently substituted for cocaine with similar potencies. Among the "NE-preferring" releasers, PAL-329 and l-methamphetamine also dose-dependently substituted for cocaine but differed in potency. PAL-169 failed to substitute for cocaine up to a dose that disrupted responding. When administered prior to cocaine, only d-amphetamine and PAL-329 significantly shifted the cocaine dose-effect function leftward indicating enhancement of cocaine's discriminative stimulus effects.
These data suggest that greater potency for NE relative to dopamine release (up to 13-fold) does not interfere with the ability of a monoamine releaser to produce cocaine-like discriminative effects but that increased serotonin release may have an inhibitory effect. Further characterization of these and other "NE-preferring" monoamine releasers should provide insight into their potential for the management of cocaine addiction.
具有明显多巴胺能作用的单胺释放剂的治疗潜力受到其高滥用倾向的阻碍。
本研究检查了几种新型“去甲肾上腺素(NE)优先”单胺释放剂相对于非选择性单胺释放剂、d-安非他命和 d-甲基苯丙胺在训练用于区分可卡因的恒河猴中的作用。与多巴胺释放相比,NE 优先释放剂对 NE 的作用大约要强 13 倍,对 5-羟色胺释放的作用强度范围为(PAL-329 < l-安非他命 < PAL-169)。
成年恒河猴通过接受 IM 可卡因(0.4mg/kg)的 30 次固定比率强化食物反应训练来区分可卡因。替代研究确定了测试药物产生可卡因样辨别刺激作用的程度及其时间过程。药物相互作用研究确定了测试药物预处理是否改变了可卡因的可辨别作用。
结果表明,可卡因、d-安非他命和 d-甲基苯丙胺均以相似的效价剂量依赖性替代可卡因。在“NE 优先”释放剂中,PAL-329 和 l-安非他命也以剂量依赖性方式替代可卡因,但效价不同。PAL-169 直至破坏反应的剂量仍未能替代可卡因。当在可卡因之前给药时,只有 d-安非他命和 PAL-329 显著将可卡因剂量-效应函数向左移动,表明增强了可卡因的辨别刺激作用。
这些数据表明,与多巴胺释放相比,对 NE 的作用更强(高达 13 倍)不会干扰单胺释放剂产生可卡因样辨别作用的能力,但增加 5-羟色胺释放可能具有抑制作用。对这些和其他“NE 优先”单胺释放剂的进一步特征描述应提供对其用于治疗可卡因成瘾的潜力的深入了解。